Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM: Intranasal Nafarelin vs Subcutaneous Triptorelin for Oocyte Maturation
NCT06763926Phase 4Recruiting
- Sponsor
- Fundación Dexeus Mujer
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nafarelin in fertility preservation (2 arms), sponsored by Fundación Dexeus Mujer. Primary endpoint: Number of metaphase 2 (MII) oocytes retrieved. Started Oct 2026; status: recruiting.
02
Drugs
nafarelin
03
Conditions
fertility preservation
Beyond the preview
Go deeper on NCT06763926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763926.